Chuangjing Capital
VC Fund
Qingdao, China
Chuangjing Capital is a VC fund in Qingdao focused on Medical and Health Care. InnoVac Capital specializes in investment management within the healthcare industry.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Chuangjing Capital invests in
Stages Chuangjing Capital invests in
Countries Chuangjing Capital invests in
Investment Focus
Industry
- Medical 3 (38%)
- Health Care 3 (38%)
- Biotechnology 2 (25%)
- Biopharma 1 (13%)
- Therapeutics 1 (13%)
Stage
- Series A 4 (50%)
- Series B 2 (25%)
- Seed 1 (13%)
- Venture - Series Unknown 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Honghu Aviation Technology
|
Honghu Aviation Technology is a specialized aviation technology company focused on providing advanced aircraft temperature control services, delivering efficient thermal management solutions that enhance operational safety, equipment reliability, and environmental control across the aviation industry. | $10.3M / Series A / Jun 03, 2026 | |
Venmedtech
|
Venmedtech engages in research and development of medical devices. | Venture - Series Unknown / May 07, 2026 | |
iRegene
|
iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases. | Series B / Sep 04, 2025 | |
Kemi Instrument
|
Kemi Instrument is a developer and manufacturer of scientific instruments and equipment, specializing in the R&D and manufacturing of scientific instruments and equipment | Series B / Aug 04, 2025 | |
Xiushi Biotechnology
|
Xiushi Biotechnology Focus on the R&D, production, sales, and technology development services of peptide products. | $14M / Series A / Jun 30, 2025 | |
|
Xiushi Biotechnology
|
Xiushi Biotechnology Focus on the R&D, production, sales, and technology development services of peptide products. | $14.2M / Seed / Oct 08, 2024 | |
Wei Gao Jie Kang Biological Material
|
Wei Gao Jie Kang Biological Material specializes in dental medical device research and development, manufacture, sales, and training. Dental implant systems (WEGO/JERICOM/Xteady), oral biomaterials, digital dental diagnosis and treatment equipment, implant surgery tool goods, oral personalized and digital restoration products, and dentalclinical consumable products are the primary items. | Series A / Aug 24, 2023 | |
Sungen Biomedical
|
Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics. | $41.7M / Series A |
Co-Investors
Xiaofanzhuo
3 deals together
Huatai Zijin Investment
2 deals together
Arshine
1 deal together
China Merchants Securities
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chuangjing Capital invest in?
Chuangjing Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chuangjing Capital last invest?
The most recent investment recorded for Chuangjing Capital closed in Jun 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
